Monitor Heron stockholder vote and regulatory clearance timeline for Q1 2027 close. Track ZYNRELEF sales trajectory toward 2028 earn-out thresholds ($65M and $95M). Watch CINVANTI competitive dynamics with Azurity's 505(b)(2) product appeal and potential at-risk launch.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $5.30entry
- T+1 · 5d ago −8.68%α −8.33% · $4.84
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CorMedix announced a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145M in cash plus ~14.6M shares of CorMedix common stock, adding four commercial products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) with ~$150M in trailing 12-month revenue. The deal is expected to close in Q1 2027, be immediately accretive to earnings and free cash flow, and generate $45M-$60M in annual operating cost synergies by year-end 2027.
Key Facts
- Upfront consideration: $145M cash plus ~14.6M shares of CorMedix common stock (fixed at $7.20/share, valued at ~$77.6M based on $5.32 closing price)
- Heron eligible for up to $55M in earn-out payments tied to ZYNRELEF 2028 net sales ($25M if >=$65M, additional $30M if >=$95M)
- Heron eligible for 5% royalty on combined CINVANTI/SUSTOL/pipeline product net sales exceeding $25M in each of 2027-2029
- Acquired products have trailing 12-month net revenue of approximately $150M
- Expected $45M-$60M in annual operating cost synergies by year-end 2027
- Pro forma 2026E combined revenue expected to be $465M-$490M
- New $150M senior secured term loan facility with Pharmakon Advisors; $75M drawn at closing, $75M available through June 2028
- Rubric Capital Management to equitize ~$38M of Heron convertible debt into CorMedix stock in 4 tranches
- Transaction unanimously approved by both boards; expected to close in Q1 2027 subject to Heron stockholder approval and regulatory clearances
- Heron to name one new member to CorMedix Board of Directors
Financial Impact
Upfront consideration of ~$222.6M ($145M cash + ~$77.6M stock) plus up to $55M earn-out; acquired revenue base of ~$150M; expected $45M-$60M cost synergies; pro forma revenue $465M-$490M
Risk Factors
- Failure to obtain Heron stockholder approval or required regulatory clearances
- Integration risks and ability to realize $45M-$60M in projected synergies
- CINVANTI faces competitive threat from Azurity's 505(b)(2) product; lower court ruling in Heron's favor is under appeal
- NOPAIN Act reimbursement for ZYNRELEF expires end of 2027, creating headwind for earn-out targets
- Dilution from ~14.6M shares issued as consideration plus potential additional shares from Rubric debt equitization
- New $150M term loan facility adds leverage and covenant compliance requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-118109 |
| Document: ea0311532-8k_cormedix.htm | 0001213900-26-118109 |
| Document: ea031153201ex99-2.htm | 0001213900-26-118109 |
| Document: 0001213900-26-118109-index-headers.html | 0001213900-26-118109 |
| Document: 0001213900-26-118109-index.html | 0001213900-26-118109 |
| Document: 0001213900-26-118109.txt | 0001213900-26-118109 |
Track record
21 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Viewing Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers